POLYMER CONJUGATES OF GLP-1
    45.
    发明申请
    POLYMER CONJUGATES OF GLP-1 有权
    GLP-1的聚合物结合

    公开(公告)号:US20100210505A1

    公开(公告)日:2010-08-19

    申请号:US12086687

    申请日:2006-12-18

    摘要: Conjugates of a GLP-I moiety may be covalently attached to one or more water-soluble polymers. For instance, a GLP-I polymer conjugate may include a GLP-I moiety releasably attached at its N-terminus to a water-soluble polymer. The GLP-I polymer conjugate may include a GLP-I moiety covalently attached to a water-soluble polymer, wherein the GLP-I moiety possesses an N-methyl substituent. The GLP-I polymer conjugate may include a GLP-I moiety covalently attached at a polymer attachment site to a water-soluble polymer, wherein the GLP-I moiety is glycosylated at a site separate from the polymer attachment site.

    摘要翻译: GLP-1部分的缀合物可以共价连接到一种或多种水溶性聚合物上。 例如,GLP-1聚合物缀合物可以包括其N-末端可释放地连接到水溶性聚合物上的GLP-1部分。 GLP-1聚合物缀合物可以包括与水溶性聚合物共价连接的GLP-1部分,其中GLP-1部分具有N-甲基取代基。 GLP-1聚合物缀合物可以包括在聚合物附着位点共价连接到水溶性聚合物上的GLP-1部分,其中GLP-1部分在与聚合物附着部位分开的位置被糖基化。

    Poly(Ethylene Glycol) Derivatives with Proximal Reactive Groups
    47.
    发明申请
    Poly(Ethylene Glycol) Derivatives with Proximal Reactive Groups 有权
    具有近端反应性基团的聚(乙二醇)衍生物

    公开(公告)号:US20090186984A1

    公开(公告)日:2009-07-23

    申请号:US12410438

    申请日:2009-03-24

    IPC分类号: C08G65/333

    摘要: An activated, substantially water-soluble poly(ethylene glycol) is provided having of a linear or branched poly(ethylene glycol) backbone and at least one terminus linked to the backbone through a hydrolytically stable linkage, wherein the terminus is branched and has proximal reactive groups. The free reactive groups are capable of reacting with active moieties in a biologically active agent such as a protein or peptide thus forming conjugates between the activated (polyethylene glycol) and the biologically active agent.

    摘要翻译: 提供活化的,基本上水溶性的聚(乙二醇),其具有直链或支链的聚(乙二醇)主链和至少一个通过水解稳定键连接至主链的末端,其中末端是支链的并具有近端反应性 团体 游离反应性基团能够与生物活性剂如蛋白质或肽中的活性部分反应,从而在活化的(聚乙二醇)与生物活性剂之间形成共轭物。

    Poly (ethylene glycol) derivatives with proximal reactive groups
    49.
    发明授权
    Poly (ethylene glycol) derivatives with proximal reactive groups 有权
    具有近端反应性基团的聚(乙二醇)衍生物

    公开(公告)号:US07528202B2

    公开(公告)日:2009-05-05

    申请号:US11799259

    申请日:2007-04-30

    摘要: An activated, substantially water-soluble poly(ethylene glycol) is provided having of a linear or branched poly(ethylene glycol) backbone and at least one terminus linked to the backbone through a hydrolytically stable linkage, wherein the terminus is branched and has proximal reactive groups. The free reactive groups are capable of reacting with active moieties in a biologically active agent such as a protein or peptide thus forming conjugates between the activated (polyethylene glycol) and the biologically active agent.

    摘要翻译: 提供活化的,基本上水溶性的聚(乙二醇),其具有直链或支链的聚(乙二醇)主链和至少一个通过水解稳定键连接至主链的末端,其中末端是支链的并具有近端反应性 团体 游离反应性基团能够与生物活性剂如蛋白质或肽中的活性部分反应,从而在活化的(聚乙二醇)与生物活性剂之间形成共轭物。

    Multi-Arm Polymer Prodrugs
    50.
    发明申请
    Multi-Arm Polymer Prodrugs 有权
    多臂聚合物前药

    公开(公告)号:US20090074704A1

    公开(公告)日:2009-03-19

    申请号:US11948767

    申请日:2007-11-30

    摘要: Provided herein are water-soluble prodrugs, compositions comprising such prodrugs, and related methods of making and administering the same. The prodrugs of the invention comprise a water-soluble polymer having three or more arms, at least three of which are typically covalently attached to an active agent, e.g., a small molecule. The conjugates of the invention provide an optimal balance of polymer size and structure for achieving improved drug loading, since the conjugates of the invention possess three or more active agents releasably attached to a multi-armed water-soluble polymer. The prodrugs of the invention are therapeutically effective, and exhibit improved properties in-vivo when compared to unmodified parent drug.

    摘要翻译: 本文提供的是水溶性前药,包含这些前药的组合物,以及制备和施用该前药的相关方法。 本发明的前药包含具有三个或更多个臂的水溶性聚合物,其中至少三个通常共价连接到活性剂例如小分子上。 本发明的共轭物提供聚合物尺寸和结构的最佳平衡以实现改善的药物负载,因为本发明的缀合物具有三种或更多种可释放地连接至多臂水溶性聚合物的活性剂。 本发明的前药在治疗上是有效的,并且与未修饰的母体药物相比在体内表现出改善的性质。